Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040895 | 0.89 | ADORA2A (0.98) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL14906451 | 0.85 | ADORA2A (0.80) | ADORA2AMEN1KMT2AADORA2BADORA1 | |
| SCHEMBL9352985 | 0.83 | MEN1 (0.77) | ADORA2AMEN1KMT2AADORA2BADORA1 | |
| SCHEMBL9353007 | 0.82 | MEN1 (0.76) | ADORA2AMEN1KMT2AADORA2BADORA1 | |
| SCHEMBL9352997 | 0.82 | MEN1 (0.76) | ADORA2AMEN1KMT2AADORA2BADORA1 | |
| SCHEMBL1527211 | 0.82 | ADORA2A (0.66) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL1527213 | 0.82 | ADORA2A (0.66) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL12150807 | 0.82 | ADORA2A (0.66) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL12031300 | 0.82 | ADORA2A (0.66) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL12300482 | 0.82 | ADORA2A (0.66) | ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820811-B2 | Pro-drugs of adenosine receptor agonists | CBT DEVELOPMENT LIMITED (GB) | 2010-10-26 | — | — | US | claimed |
| US-20080009461-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-01-10 | — | — | US | claimed |
| US-7820811-B2 | Pro-drugs of adenosine receptor agonists | CBT DEVELOPMENT LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820811-B2 | Pro-drugs of adenosine receptor agonists | CBT DEVELOPMENT LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-7820811-B2 | Pro-drugs of adenosine receptor agonists | CBT DEVELOPMENT LIMITED (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20080009461-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009461-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009461-A1 | Therapeutic compounds | BIOVITRUM AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009461-A1 | Therapeutic compounds | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885MEN1 2737/4885KMT2A 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.